Welcome to our dedicated page for Establishment Labs Hldgs news (Ticker: ESTA), a resource for investors and traders seeking the latest updates and insights on Establishment Labs Hldgs stock.
News and updates for Establishment Labs Holdings Inc. (NASDAQ: ESTA) center on its role as a global medical device company dedicated to women’s health, particularly in breast aesthetics and reconstruction. Company announcements frequently highlight developments in its Motiva breast implant portfolio, minimally invasive platforms, and reconstruction technologies, as well as financial performance and corporate events.
Investors and clinicians following ESTA news can expect regular coverage of quarterly and annual financial results, including revenue trends, margins, and cash position as disclosed in earnings releases and accompanying conference calls. The company also reports on financing arrangements, such as amendments to its credit agreement and access to additional term loan tranches, through Form 8-K filings and press releases.
Product and clinical news is a recurring theme. Establishment Labs issues updates on regulatory milestones, such as FDA submissions and indications for Motiva implants in breast augmentation and reconstruction. It also shares outcomes from clinical studies, including prospective trials of Mia Femtech, and annual Post-Market Surveillance reports summarizing real-world performance data for Motiva implants across global markets.
Conference participation and investor outreach are another focus of ESTA news. The company announces presentations at major healthcare investment conferences, including events hosted by J.P. Morgan and Jefferies, where its leadership discusses strategy, product platforms, and market opportunities. For users tracking the ESTA stock, this news feed provides a consolidated view of financial disclosures, regulatory updates, clinical evidence, and corporate presentations related to Establishment Labs.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) announced its participation in two investment conferences. CEO Juan José Chacón-Quirós and Interim CFO Raj Denhoy will attend the Jefferies London Healthcare Conference on November 16, 2021, and the Canaccord Genuity Virtual MedTech Forum on November 18, 2021. Live webcasts of their presentations will be available on the Establishment Labs investor relations website, with archived versions accessible afterward. The company specializes in breast aesthetics and reconstruction, offering innovative silicone gel-filled implants globally.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) reported third-quarter 2021 revenue of $29.0 million, up 27.6% year-over-year. Gross profit margin improved to 67.6%, while operating expenses increased to $28.7 million, driven by a return to normal business conditions. The company raised its 2021 revenue guidance to $124 million to $128 million, a growth of 46% to 51% over 2020. A net loss of $9.0 million was recorded. The company launched the Motiva Flora® tissue expander, and its Motiva implants are on track for U.S. and China market entry.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) has appointed Jeffrey Bettinger as Global Head of People. Bettinger, previously Chief People and Places Officer at Nu Skin, joins the executive team with a focus on culture and human capital strategy. CEO Juan José Chacón-Quirós emphasized the importance of people and culture for the company's upcoming growth and global expansion. Measuring past success in leadership development, Bettinger aims to innovate within the Femtech industry to positively impact women's lives. Establishment Labs specializes in breast aesthetics and has delivered over 1.8 million Motiva Implants in 80+ countries.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) will announce its financial results for Q3 2021 on November 9, 2021, before market opens. Following this, a conference call is scheduled at 8:30 AM ET to discuss the results. Establishment Labs specializes in women's health, particularly in breast aesthetics and reconstruction, offering products like Motiva Implants®. Since 2010, over 1.6 million implants have been distributed worldwide in over 80 countries. The company is focused on regulatory approvals for its innovative products.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) launched JOY™, a new patient-centric breast aesthetics program featuring the latest Motiva Ergonomix2® implants. JOY offers comprehensive support, including the Motiva Woman’s Choice Program™, which provides financial assistance for implant removal, and surgeon options for reverse procedures at no additional cost. Announced at the 6th World Symposium on Ergonomic Implants in Italy, JOY aims to enhance the experience for women undergoing breast surgery by combining advanced implant technology with specialized surgeon training.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) announced its support for Breast Cancer Awareness Month in October, focusing on improving access to breast reconstruction. The company will implement the Pink is for Power program in Brazil, providing 200 women with reconstruction surgeries. Key events planned include the Motiva Breast Health Day in Barcelona and the Rosé for Reconstruction event in Italy. With the recent launch of their Motiva Flora tissue expander, Establishment Labs aims to enhance clinical outcomes for breast cancer patients.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) officially launched its Motiva Flora® tissue expander in Europe during a symposium at the London Breast Meeting on September 2, 2021. This RFID-enabled device aims to enhance post-mastectomy reconstruction, improving patient comfort through advanced biocompatibility and MRI imaging capabilities. CEO Juan José Chacón-Quirós highlighted the significance of Flora in capturing a substantial market share in breast reconstruction, projecting improved outcomes for women. Motiva Flora is not yet approved for distribution in the U.S.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) has announced the launch of Motiva Flora®, a new tissue expander in Europe and CE Mark countries, set for September 2, 2021. This innovative product features patented SmoothSilk® surface technology and RFID-enabled ports, aiming to enhance imaging and patient outcomes. The event will include presentations from medical professionals and discussion on commercialization plans. Currently, Motiva Flora is not approved for distribution in the U.S.
Summary not available.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) has announced participation in the UBS Genomics 2.0 and MedTech Innovations Summit from August 10-12, 2021. CEO Juan José Chacón-Quirós and Interim CFO Raj Denhoy will address attendees on August 12 at 8:00 am ET. A live webcast of their presentation will be available on the company's investor relations website, along with an archived version post-event. Establishment Labs specializes in women's health, notably breast aesthetics and reconstruction, marketing over 1.6 million Motiva Implants® worldwide since 2010.